Background. Although infliximab (IFX) has been available since 2005, there are very little data on the long-term drug survival of\ninfliximab in real-life. Objective. Our aim was to identify and describe psoriasis patients treated with IFX for longer than 6 years.\nMethods. Psoriasis patients treated with IFX for longer than 6 years were retrospectively included. Demographic and clinical data\nwere collected in May 2018. Results. Between January 2005 and December 2012, 43 patients were maintained on IFX for 6 years or\nlonger. IFX was introduced as a 4.5 line of systemic therapy. The mean duration of IFX treatment was 8.5 years (6â??12). In May\n2018, 30 patients (70%) were still maintained on IFX at 4â??6 mg/kg every 8â??10 weeks with an efficiency of about 100%. IFX was\nstopped in 13 patients (30%) mainly for loss of efficacy in 6 patients (46%). Three patients developed solid cancer including bladder\ncancer, lung cancer, and prostate cancer. Limitation. Retrospective study. Conclusion. We report the efficacy and safety of IFX\nmaintained for up to 12 years in psoriasis patients. Thelong-term use of IFX was associated with a high BMI confirming the critical\nrole of weight-based dosing for this drug.
Loading....